中国中药杂志2026，Vol.51Issue(13)：3646-3656,11.DOI:10.19540/j.cnki.cjcmm.20260405.201
葛根素抗抑郁的研究进展
Research progress of puerarin antidepressant
摘要
Abstract
Puerarin,an isoflavonoid compound derived from TCM Puerariae Lobatae Radix,has garnered increasing attention for its potential in treating depression.By systematically reviewing relevant domestic and international research,this paper elaborated on the multi-target molecular mechanisms underlying the antidepressant effects of puerarin,including the regulation of the gut microbiota-gut-brain axis,inhibition of neuroinflammation,promotion of neurotrophy and neurogenesis,amelioration of oxidative stress and mitochondrial function,modulation of neurotransmitters and the hypothalamic-pituitary-adrenal(HPA)axis,and epigenetic modifications.The paper further highlighted its synergistically therapeutic potential in comorbidity models such as diabetes with depression and post-stroke depression,as well as its application in compound compatibility and the current status of clinical translation research.Despite breakthroughs in emerging fields like the regulation of neural circuit plasticity,intervention in neuronal apoptosis,and modulation of non-coding RNA networks,the clinical application of puerarin is primarily limited by its pharmacokinetic drawbacks,such as poor water solubility and low bioavailability,coupled with a lack of high-quality clinical evidence.This paper aims to provide a theoretical basis for developing puerarin into a novel antidepressant by deeply analyzing the complex network of its mechanisms and evaluating its prospects for clinical translation.关键词
葛根素/抑郁症/共病治疗/复方配伍/生物利用度/神经环路/非编码RNAKey words
puerarin/depression/comorbidity treatment/compound compatibility/bioavailability/neural circuit/non-coding RNA引用本文复制引用
游佩进,闵忠云,刘文杰,吕志远,郝娟,孙涛..葛根素抗抑郁的研究进展[J].中国中药杂志,2026,51(13):3646-3656,11.基金项目
2025年乌鲁木齐市"红山英才"计划项目 （）
